Vincerx Pharma, Inc.
VINC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $1 | $1 | $0 |
| Gross Profit | $0 | -$1 | -$1 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $15 | $28 | $52 | $40 |
| G&A Expenses | $16 | $14 | $19 | $23 |
| SG&A Expenses | $16 | $14 | $19 | $23 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $31 | $42 | $71 | $63 |
| Operating Income | -$31 | -$43 | -$69 | -$63 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1 | $2 | $6 | $23 |
| Pre-Tax Income | -$30 | -$40 | -$63 | -$39 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$30 | -$40 | -$65 | -$39 |
| % Margin | – | – | – | – |
| EPS | -5.75 | -6.84 | -10.86 | -8.3 |
| % Growth | 15.9% | 37% | -30.8% | – |
| EPS Diluted | -5.75 | -6.84 | -10.86 | -8.3 |
| Weighted Avg Shares Out | 5 | 6 | 6 | 5 |
| Weighted Avg Shares Out Dil | 5 | 6 | 6 | 5 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $1 | $1 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $1 | $1 | $0 |
| EBITDA | -$31 | -$39 | -$62 | -$39 |
| % Margin | – | – | – | – |